Makro-Albumon

Macrosalb, the active ingredient in Makro-Albumon, is a pharmaceutical compound presented as an intravenous preparation for clinical use. It is employed in specialized medical settings where plasma protein supplementation may be required.

GNH USA supplies Makro-Albumon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

Makro-Albumon is an intravenous albumin solution used in conditions where plasma oncotic pressure support is needed.

- Hypoalbuminemia: helps restore normal serum albumin levels and oncotic pressure. - Acute volume depletion: contributes to plasma volume expansion during shock or major surgery. - Liver disease with ascites: may be used to manage fluid balance in selected patients.

Makro-Albumon, like other albumin solutions, may be associated with adverse reactions.

Common Side Effects: - Fever or chills during infusion. - Mild hypotension or transient blood pressure changes. - Headache or dizziness. - Nausea or mild gastrointestinal discomfort. - Local irritation at the infusion site. - Transient increase in serum calcium levels.

Serious or Rare Side Effects: - Anaphylactic or severe allergic reactions. - Volume overload leading to pulmonary edema. - Cardiac arrhythmias in susceptible patients. - Hemolysis or red blood cell aggregation. - Severe electrolyte disturbances. - Coagulopathy or bleeding complications.

Before using Makro-Albumon, consider the following safety measures.

- Assess fluid status: evaluate for signs of overload or dehydration. - Cardiac function: monitor patients with heart failure or coronary disease. - Renal impairment: adjust volume administration in patients with reduced kidney function. - Electrolyte balance: check serum calcium and potassium levels prior to infusion. - Allergic history: verify no prior severe reactions to albumin products. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Makro-Albumon may interact with other agents affecting fluid balance or coagulation.

Major Interactions (Avoid): - Diuretics: concurrent use can exacerbate hypovolemia. - ACE inhibitors or ARBs: may increase risk of hypotension. - Anticoagulants: albumin can alter plasma protein binding, affecting drug levels.

Moderate Interactions (Monitor Closely): - Calcium channel blockers: monitor for additive blood pressure effects. - Immunosuppressants: observe for changes in drug pharmacokinetics. - Other plasma expanders: avoid cumulative volume overload.